Building for Local Organizations in the Republic of South Africa and the Kingdoms of Lesotho and Swaziland; Notice of Availability of Funds-Amendment, 51355 [05-17177]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 167 / Tuesday, August 30, 2005 / Notices
comments to Dr. Armitage by mail or
courier. Commenters planning to attend
the meeting in person are asked to bring
35 copies of their comments for public
distribution. Oral Comments: Requests
to provide oral comments must be in
writing (e-mail or fax) and received by
Dr. Armitage no later than September
14, 2005 to reserve time on the meeting
agenda. Presentation time for oral
comment will typically be about five
minutes per speaker, but may be
reduced depending on time availability
and the number of requests.
Meeting Accommodations:
Individuals requiring special
accommodation to access the public
meeting listed above should contact the
DFO at least five business days prior to
the meeting so that appropriate
arrangements can be made.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: August 23, 2005.
Anthony Maciorowski,
Acting Director, EPA Science Advisory Board
Staff Office.
[FR Doc. 05–17198 Filed 8–29–05; 8:45 am]
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held via teleconference on September
22, 2005 from 1:30 p.m. to 5 p.m.
Location: NIH campus, Food and Drug
Administration Bldg. 29B, Conference
Room C, 8800 Rockville Pike, Bethesda,
MD. This meeting will be held by
teleconference. The public is welcome
to attend the meeting at the above
location. A speaker phone will be
provided at the specified location for
public participation in this meeting.
Important information about
transportation and directions to the NIH
campus, parking, and security
procedures is available on the internet
at https://www.nih.gov/about/visitor/
index.htm. Visitors must show two
forms of identification such as a Federal
employee badge, driver’s license,
passport, green card, etc. If you are
planning to drive to and park on the
NIH campus, you must enter at the
South Drive entrance of the campus,
which is located on Wisconsin Ave. (the
medical center metro entrance), and
allow extra time for vehicle inspection.
Detailed information about security
procedures is located at https://
www.nih.gov/about/visitorsecurity.htm.
Due to the limited available parking,
visitors are encouraged to use public
transportation.
BILLING CODE 6560–50–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[RFA AA169]
Building for Local Organizations in the
Republic of South Africa and the
Kingdoms of Lesotho and Swaziland;
Notice of Availability of Funds—
Amendment
A notice announcing the availability
of Fiscal Year (FY) 2005 funds for a
cooperative agreement for Building for
Local Organizations in the Republic of
South Africa and the Kingdoms of
Lesotho and Swaziland, was published
in the Federal Register, August 12,
2005, Volume 70, Number 155, pages
47209–47214.
This notice is amended as follows:
Page 47210, Approximate Total
Funding: delete $500,000, and replace
with $5,000,000. Page 47210,
Approximate Average Award, delete
$100,000, and replace with $500,000–
$1,000,000. Page 47210, Ceiling of
Award Range, delete $100,000, and
replace with $1,000,000.
Dated: August 23, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention,
U.S. Department of Health and Human
Services.
[FR Doc. 05–17177 Filed 8–29–05; 8:45 am]
BILLING CODE 4163–18–U
VerDate Aug<18>2005
15:17 Aug 29, 2005
Jkt 205001
Food and Drug Administration
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
Contact Person: Christine Walsh or
Denise Royster, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314 or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
51355
3014512391. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The committee will hear an
overview of the research of the
Laboratory of Retroviruses and the
Laboratory of Immunoregulation,
Division of Viral Products, and the
Laboratory of Respiratory and Special
Pathogens and the Laboratory of
Methods Development and Quality
Control, Division of Bacterial Parasitic
and Allergenic Products, Office of
Vaccines Research and Review, Center
for Biologics Evaluation and Research
(CBER), and in closed session will
discuss the reports from the Laboratory
Site Visits of April 18 and 19, 2005, and
June 16, 2005.
Procedure: On September 22, 2005,
from 1:30 p.m. to 4 p.m., the meeting is
open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by September 15, 2005. Oral
presentations from the public will be
scheduled between approximately 3
p.m. to 4 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before September 15, 2005, and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation.
Closed Committee Deliberations: On
September 22, 2005, from 4 p.m. to 5
p.m. the meeting will be closed to
permit discussion where disclosure
would constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The committee will discuss
a review of internal research programs
in the Office of Vaccines Research and
Review, Division of Viral Products and
Division of Bacterial Parasitic and
Allergenic Products, CBER.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Christine
Walsh or Denise Royster (see CONTACT
PERSON) at least 7 days in advance of the
meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 70, Number 167 (Tuesday, August 30, 2005)]
[Notices]
[Page 51355]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-17177]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[RFA AA169]
Building for Local Organizations in the Republic of South Africa
and the Kingdoms of Lesotho and Swaziland; Notice of Availability of
Funds--Amendment
A notice announcing the availability of Fiscal Year (FY) 2005 funds
for a cooperative agreement for Building for Local Organizations in the
Republic of South Africa and the Kingdoms of Lesotho and Swaziland, was
published in the Federal Register, August 12, 2005, Volume 70, Number
155, pages 47209-47214.
This notice is amended as follows:
Page 47210, Approximate Total Funding: delete $500,000, and replace
with $5,000,000. Page 47210, Approximate Average Award, delete
$100,000, and replace with $500,000-$1,000,000. Page 47210, Ceiling of
Award Range, delete $100,000, and replace with $1,000,000.
Dated: August 23, 2005.
William P. Nichols,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention, U.S. Department of Health and Human Services.
[FR Doc. 05-17177 Filed 8-29-05; 8:45 am]
BILLING CODE 4163-18-U
